Neuropsychopharmacology is an international scientific journal and the official publication of the American College of Neuropsychopharmacology (ACNP). This journal focuses upon clinical and basic science contributions that advance our understanding of the brain and behavior, especially as related to the molecular, cellular, physiological and psychological properties of agents acting within the central nervous system and the identification of the new molecular targets for the development of the next generation of drugs. While original reports are preferred, mini-reviews and perspectives are invited by the editorial office.
With a 2021 impact factor of 8.294, Neuropsychopharmacology (NPP) ranks 19 of 155 Psychiatry journals, 21 of 279 Pharmacology and Pharmacy journals, and 31 of 274 Neuroscience journals. The journal has a 2021 CiteScore of 13.0 In 2021, on average, articles received a first decision from NPP within 30 days (with review); manuscripts publish online in 21 days from the time they are received by production.
In 2021, NPP saw more than 4 million article downloads. That year, the journal’s bimonthly podcasts, or BrainPods, generate roughly 225 weekly listens on topics that showcase advancements in our understanding of the brain and behavior. Check us out at www.nature.com/npp!
In view of the interdisciplinary nature of the field, particular emphasis is placed on:
studies that advance the biological bases of normal and pathological behavior
the nature, etiology and pathophysiology of neuropsychiatric disorders
biologically relevant aspects of the epidemiology, diagnosis, and treatment of these disorders
the basic mechanisms by which psychopharmacological agents exert their effect
Drs. Tony P. George, M.D., FRCPC & Lisa Monteggia, Ph.D.
Dr. Keri Martinowich, Ph.D.
NPP Social Media Editor
Instructions for Authors
Submission & Editorial Policy
Instructions for Reviewers
Criteria for Publication
(includes initial evaluation for compliance)
(includes suitability for review and selection of reviewers)
(includes strict guidelines)
Conflict of Interest
(includes fairness and potential biases)
(includes breaches of publication policy)
Are you receiving Neuropsychopharmacology e-alerts?
Sign up with your e-mail address to receive monthly table of contents alerts and keep informed with Neuropsychopharmacology news and announcements. Each e-alert features the latest journal commentaries, circumspectives, original research and review articles.
BRAD 2023 is just around the corner! Register for your BRAD box by April 1st to celebrate on April 20th. Any celebration - big or small - is important as we work together to show support for animal research and to educate the public on the role of animals in medical advancements.
In Memoriam to Dr. Robert Hirschfeld, @ACNPorg Emeritus Fellow. Dr. Hirschfeld was well known for development of the Mood Disorder Questionnaire (MDQ), one of the most widely used screening assessments for bipolar disorder.
It's #WomensHistoryMonth! This month, and throughout the year, we celebrate the legacies of women in the field of psychiatry, both past and present, who have advanced the field and improved the lives of those with mental health issues.